FDA approval broadens label for Sanofi's Thymoglobulin

25 April 2017

French pharma major Sanofi (Euronext: SAN) says that the US Food and Drug Administration has approved Thymoglobulin [anti-thymocyte globulin (rabbit)] as a treatment against acute rejection in patients receiving a kidney transplant.

It’s the first new indication that Thymoglobulin has received approval for since 1998, when the drug was cleared for use in the USA.

468,000 patients in the USA are currently on dialysis for kidney failure, including an estimated 100,000 who are waiting for a kidney transplant. Transplantation carries a risk of acute rejection, which can lead to complications and loss of the transplanted organ.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK